Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 700 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 700 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.28, for a total value of $82,796.00. Following the sale, the insider now directly owns 18,831 shares in the company, valued at approximately $2,227,330.68. The trade was a 3.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Julie Cooke also recently made the following trade(s):

• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Stock Up 0.3 %

NBIX traded up $0.33 during trading on Wednesday, reaching $117.18. 2,148,807 shares of the company’s stock were exchanged, compared to its average volume of 1,350,825. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The company has a market capitalization of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. The business has a 50 day moving average price of $138.49 and a 200 day moving average price of $131.02.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, research analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays increased their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a report on Friday, February 7th. HC Wainwright dropped their price target on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Bank of America reduced their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Wedbush cut their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the business. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $236,000. Plato Investment Management Ltd raised its position in Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the last quarter. Swiss National Bank lifted its holdings in Neurocrine Biosciences by 1.4% during the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after buying an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp bought a new position in Neurocrine Biosciences in the 3rd quarter valued at $3,236,000. Finally, KBC Group NV increased its stake in shares of Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after buying an additional 8,332 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.